• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xilio Therapeutics, Inc. - Common Stock (NQ:XLO)

7.560 +0.050 (+0.67%)
Delayed Quote Updated: 4:00 PM EST, Nov 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,103
Open 7.430
Bid (Size) 7.000 (300)
Ask (Size) 9.430 (100)
Prev. Close 7.510
Today's Range 7.065 - 7.600
52wk Range 6.465 - 11.20
Shares Outstanding 51,827,910
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
CytoDyn Appoints Lauren Wilcoxen, Ph.D., as Chief Operating Officer and Head of Regulatory Affairs
November 17, 2026
From CytoDyn Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates
November 10, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 32.5% below 52-week high
7.560
6.4752W Low 11.2052W High
1 Week 10.4% below 1-week high
7.071W Low 8.441W High

Xilio Therapeutics, Inc. - Common Stock (XLO) traded between $6.47 and $11.20 over the past 52 weeks and last traded at $7.56, 32.5% below its 52-week high. Over the past week it ranged between $7.07 and $8.44.

Past 12 Months
-1.8%
-10.3%
-18.1%
-8.4%
-19.6%
-28.0%
1W -$0.14
1M -$0.87
3M -$1.67
6M -$0.69
YTD -$1.84
1Y -$2.94

XLO was -28.0% over the past year, -8.4% over six months, -19.6% year to date, -1.8% in the last week.

12 Months vs Market
XLO
-28.0%
DIA
+5.0%
SPY
+5.7%
QQQ
+3.9%
IWM
+12.0%

Over the past 12 months XLO returned -28.0% versus DIA (Dow) +5.0%, SPY (S&P 500) +5.7%, QQQ (Nasdaq 100) +3.9% and IWM (Russell 2000) +12.0%.

Volume & Liquidity 1.76× 3-mo avg
Today 20,103 3-mo avg 11.4K
1W
9.3K
1M
13.5K
3M
11.4K
6M
22.7K
YTD
31.6K
1Y
31.7K

XLO most recently traded 20,103 shares against a 3-month average daily volume of 11.4K.

More News

Read More
News headline image
Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference
November 03, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC
October 26, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
September 28, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates
August 12, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 06, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
June 29, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
May 12, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 07, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
April 17, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
April 16, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
March 23, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
March 17, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
March 12, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
March 02, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 02, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA
February 19, 2026
Via Finterra
Topics Lawsuit
News headline image
Xilio Therapeutics Announces Pricing of Underwritten Offering
February 11, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
January 08, 2026
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
November 13, 2025
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
November 10, 2025
Via Benzinga

Frequently Asked Questions

Is Xilio Therapeutics, Inc. - Common Stock publicly traded?
Yes, Xilio Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Xilio Therapeutics, Inc. - Common Stock trade on?
Xilio Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Xilio Therapeutics, Inc. - Common Stock?
The ticker symbol for Xilio Therapeutics, Inc. - Common Stock is XLO on the Nasdaq Stock Market
What is the current price of Xilio Therapeutics, Inc. - Common Stock?
The current price of Xilio Therapeutics, Inc. - Common Stock is 7.560
When was Xilio Therapeutics, Inc. - Common Stock last traded?
The last trade of Xilio Therapeutics, Inc. - Common Stock was at 11/20/26 04:00 PM ET
What is the market capitalization of Xilio Therapeutics, Inc. - Common Stock?
The market capitalization of Xilio Therapeutics, Inc. - Common Stock is 391.82M
How many shares of Xilio Therapeutics, Inc. - Common Stock are outstanding?
Xilio Therapeutics, Inc. - Common Stock has 392M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap